DALLAS, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing, is proud to announce the launch of its new ketamine hair testing solution. This innovative testing method marks a significant advancement in the detection and prevention for a drug-free workplace and community.
Ketamine, a powerful dissociative anesthetic and emerging drug of abuse, poses a growing concern for employers, educators, and law enforcement agencies. With the introduction of this new testing service, Psychemedics aims to equip organizations with the tools needed to identify and address ketamine use effectively.
Key Features and Benefits of Ketamine Hair Testing
“We are thrilled to introduce ketamine hair testing as part of our commitment to delivering the most reliable and comprehensive drug testing solutions,” said Brian Hullinger, CEO and President of Psychemedics. “This new offering underscores our dedication to innovation and our mission to support organizations in maintaining safe and drug-free environments.”
Psychemedics’ ketamine hair testing service is now available to clients and partners. For more information about this new service or to schedule a consultation, please contact Psychemedics at This email address is being protected from spambots. You need JavaScript enabled to view it. or visit our website at https://www.psychemedics.com.
About Psychemedics
Psychemedics Corporation is a leading global provider of innovative hair testing for drugs of abuse. With a commitment to accuracy and reliability, the company offers cutting-edge drug testing solutions. Psychemedics Corporation is dedicated to providing valuable insights and maintaining the highest standards in substance abuse testing.
Investor Relations:
Phone: 978-206-8220
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.67 |
Daily Volume: | 0 |
Market Cap: | US$15.730M |
November 12, 2024 August 13, 2024 March 28, 2024 November 27, 2023 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load